Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 10496285.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors reviewed the results of neoadjuvant (preradiation) procarbazine, CCNU, and vincristine chemotherapy for anaplastic oligodendrogliomas because, increasingly, chemotherapy is prescribed before radiation for oligodendroglial neoplasms. The data indicate that 70% of patients respond to neoadjuvant chemotherapy, whereas 30% require early radiation because they either have chemoresistant tumors or experience unacceptable chemotoxicity.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Brain Neoplasms
- Oligodendroglioma